Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular function after anisoylated plasminogen streptokinase activator complex.

M Been1, A L Muir, D P de Bono

  • 1Department of Cardiology, Freeman Hospital, Newcastle upon Tyne.

Drugs
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dilemma in the cardiac catheter laboratory.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2010
Same author

Oxygen transport in acute pulmonary oedema and in acute exacerbations of chronic bronchitis.

British medical journal·2010
Same author

Massive right atrial myxoma causing exertional dyspnoea.

European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology·2007
Same author

Subclavian artery stenosis as a cause for recurrent angina after LIMA graft stenting.

Heart (British Cardiac Society)·2003
Same author

Predictors of mortality in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Heart (British Cardiac Society)·2003
Same author

Intermittent opening of a mitral valve tilting disc prosthesis 23 years after implantation caused by circumferential pannus.

Heart (British Cardiac Society)·2003

Early administration of anisoylated plasminogen streptokinase activator complex (APSAC) preserves left ventricular function after myocardial infarction. Prompt treatment maximizes therapeutic benefits, highlighting the importance of timely thrombolytic therapy.

Area of Science:

  • Cardiology
  • Thrombolytic Therapy
  • Myocardial Infarction Research

Background:

  • Left ventricular function reduction post-myocardial infarction (MI) is a key outcome measure.
  • Thrombolytic therapy aims to limit infarct size and preserve cardiac function.
  • Anisoylated plasminogen streptokinase activator complex (APSAC) is a thrombolytic agent used in acute MI.

Purpose of the Study:

  • To evaluate the efficacy of APSAC in preserving left ventricular function after acute myocardial infarction.
  • To assess the impact of treatment timing and infarct location on therapeutic outcomes.
  • To determine the early and late effects of APSAC on global left ventricular ejection fraction.

Main Methods:

  • Radionuclide ventriculography used in 91 patients across 3 studies.

Related Experiment Videos

  • APSAC administered within 4 hours of acute myocardial infarction onset.
  • Left ventricular ejection fraction (LVEF) measured at 10 days and 6 months post-treatment.

    • Main Results:

    • Successful APSAC therapy preserved LVEF in anterior infarctions at 10 days.
    • Therapeutic benefit diminished with longer symptom duration before treatment.
    • Benefit was less pronounced in inferior infarctions, with no significant LVEF improvement by 6 months in some groups.
    • Early treatment led to greater LVEF preservation and potentially faster functional recovery.

    Conclusions:

    • Early administration of APSAC is crucial for preserving left ventricular function following acute myocardial infarction.
    • Timing of thrombolytic therapy significantly influences patient outcomes.
    • Infarct location affects the degree of benefit observed with APSAC treatment.